Publication #8187

Reference
Drug alert 23/2024
Name
Drug Alert Class 3 Drug Alert 23 2024 – Class 3 medicines defect information – action within 5 days – Teva UK Ltd – GoResp Digihaler
Categories
Scottish Government Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS Scotland Drugs Safety Risks Pharmaceutical Industry Medicines Recall
Description
Teva UK Limited has informed the MHRA that it plans to withdraw from further sale all batches of GoResp Digihaler (budesonide and formoterol fumarate dihydrate) and the linked Digihaler App for commercial reasons. The inhalers containing the medicinal product are being withdrawn from the market because the App is no longer being supported, there is no product quality issue with the medicine itself. 
From 1 June 2024 the Digihaler App described in the Patient Information Leaflet is no longer available for download from the Apple App Store and Google Play store. This means users will not be able to download the app, sign up, log in or load any new data. 
This affects a very small number of patients who are currently using the App. However, the notification is being sent wider to ensure awareness and recall remaining stock. 

Contact Name
Irene Fazakerley
Contact Address
Contact Phone

Created
2024-06-18 11:56:00


Click to go back to homepage